Clinical Trials

Clinical trials are the driving force behind our efforts to advance innovative therapies that may help patients and their families fighting a broad range of cancers. We conduct these trials to support the development of medicines that have the potential to be safe and effective options for our patients.

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518

Description of the Study

This is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors. The purpose of this study is to define the dosing schedule, and maximally tolerated dose to be used in subsequent development of PRT2527.

Eligibility:

Age18+
Sex All
StatusActive, Not Recruiting

A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies

NCT05665530

Description of the Study

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib.

Eligibility:

Age18+
Sex All
StatusRecruiting